{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:04:45Z","timestamp":1789772685595,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T00:00:00Z","timestamp":1410220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00228-014-1746-2","type":"journal-article","created":{"date-parts":[[2014,9,7]],"date-time":"2014-09-07T21:54:10Z","timestamp":1410126850000},"page":"1385-1393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Outcomes of off-label drug uses in hospitals: a multicentric prospective study"],"prefix":"10.1007","volume":"70","author":[{"given":"I.","family":"Dan\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Agust\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vallano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alerany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gratac\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M. Cano","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Bonafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,9]]},"reference":[{"key":"1746_CR1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.18773\/austprescr.2013.075","volume":"36","author":"R Day","year":"2013","unstructured":"Day R (2013) Off-label prescribing. Aust Prescr 36:182\u20133","journal-title":"Aust Prescr"},{"key":"1746_CR2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","volume":"166","author":"DC Radley","year":"2006","unstructured":"Radley DC, Finkelstein SN, Stafford R (2006) Off-label prescribing among office-based physicians. Arch Intern Med 166:1021\u20136","journal-title":"Arch Intern Med"},{"key":"1746_CR3","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archinternmed.2012.340","volume":"172","author":"T Eguale","year":"2012","unstructured":"Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R (2012) Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med 172:781\u20138","journal-title":"Arch Intern Med"},{"key":"1746_CR4","doi-asserted-by":"crossref","unstructured":"Roehr B (2012) Free speech rights outweight restrictions on promoting drugs off-label, court rules. BMJ 345:e8324.","DOI":"10.1136\/bmj.e8324"},{"key":"1746_CR5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jama.297.7.683","volume":"297","author":"T Hampton","year":"2007","unstructured":"Hampton T (2007) Experts weight in on promotion, prescription off-label drugs. JAMA 297:683\u20134","journal-title":"JAMA"},{"key":"1746_CR6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jama.2012.207972","volume":"309","author":"AS Kesselheim","year":"2013","unstructured":"Kesselheim AS, Mello MM, Avorn J (2013) FDA regulation of off-label drug promotion under attack. JAMA 309:445\u20136","journal-title":"JAMA"},{"key":"1746_CR7","unstructured":"Royal Decree 1015\/2009 of 19 June, on the availability of drugs in special situations is regulated. Official State Bulletin. No. 174 Monday, 20 July 2009. Sec.I. Page 60904 [Document in Spanish] Available at: http:\/\/www.boe.es\/boe\/dias\/2009\/07\/20\/pdfs\/BOE-A-2009-12002.pdf"},{"key":"1746_CR8","unstructured":"CatSalut (2010) Instruction 05\/2010. Use of drugs approved under conditions other than those laid down in the technical details. [Document in Catalan] Available at: http:\/\/www20.gencat.cat\/docs\/salut\/Minisite\/catsalut\/Proveidors_professionals\/normatives_instruccions\/Documents\/Arxius\/instruccio_05_2010.pdf"},{"key":"1746_CR9","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1445-5994.2012.02751.x","volume":"42","author":"JD Mellor","year":"2012","unstructured":"Mellor JD, Van Koeverden P, Yip SW, Thakerar A, Kirsa SW, Michael M (2012) Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme. Intern Med J 42:1224\u20139","journal-title":"Intern Med J"},{"key":"1746_CR10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/030089160909500601","volume":"95","author":"Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM)","year":"2009","unstructured":"Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM) (2009) Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey. Tumori 95:647\u201351","journal-title":"Tumori"},{"key":"1746_CR11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00228-014-1662-5","volume":"70","author":"M Joerger","year":"2014","unstructured":"Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thuerlimann B, Cerny T (2014) Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 70:719\u201325","journal-title":"Eur J Clin Pharmacol"},{"key":"1746_CR12","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00228-013-1518-4","volume":"69","author":"I Dan\u00e9s","year":"2013","unstructured":"Dan\u00e9s I, Agust\u00ed A, Vallano A, Mart\u00ednez J, Alerany C, Ferrer A, L\u00f3pez A, Cort\u00e9s-Hern\u00e1ndez J, Bosch JA (2013) Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol 69:1689\u201399","journal-title":"Eur J Clin Pharmacol"},{"key":"1746_CR13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/imj.12206","volume":"43","author":"K O\u2019Connor","year":"2013","unstructured":"O\u2019Connor K, Liddle C (2013) Prospective data collection of off-label use of rituximab in Australian public hospitals. Intern Med J 43:863\u201370","journal-title":"Intern Med J"},{"key":"1746_CR14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00228-002-0479-9","volume":"58","author":"GW Jong","year":"2002","unstructured":"Jong GW, van der Linden PD, Bakker EM, van der Lely N, Eland IA, Stricker BH, van den Anker JN (2002) Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol 58:293\u2013297","journal-title":"Eur J Clin Pharmacol"},{"key":"1746_CR15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1542\/peds.111.2.291","volume":"111","author":"E Schirm","year":"2003","unstructured":"Schirm E, Tobi H (2003) Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 111:291\u2013295","journal-title":"Pediatrics"},{"key":"1746_CR16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2710.2008.01005.x","volume":"34","author":"L Lindell-Osuagwu","year":"2009","unstructured":"Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H (2009) Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34:277\u201387","journal-title":"J Clin Pharm Ther"},{"key":"1746_CR17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1824-7288-40-12","volume":"40","author":"P Langerov\u00e1","year":"2014","unstructured":"Langerov\u00e1 P, Vrtal J, Urb\u00e1nek K (2014) Incidence of unlicensed and off-label prescription in children. Ital J Pediatr 40:12","journal-title":"Ital J Pediatr"},{"key":"1746_CR18","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/imj.12207","volume":"43","author":"J Chay","year":"2013","unstructured":"Chay J, Donovan P, Cummins S, Kubler P, Pillans P (2013) Experience with low dose rituximab in off-label indications at two tertiary hospitals. Int Med J 43:871\u201382","journal-title":"Int Med J"},{"key":"1746_CR19","doi-asserted-by":"crossref","first-page":"e31894","DOI":"10.1371\/journal.pone.0031894","volume":"7","author":"AS Kesselheim","year":"2012","unstructured":"Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J (2012) The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS ONE 7:e31894","journal-title":"PLoS ONE"},{"key":"1746_CR20","unstructured":"U.S.National Institutes of Health (2012) Clinicaltrials.gov. Available at: http:\/\/clinicaltrials.gov\/ct2\/home . Accessed 20 Dec 2012"},{"key":"1746_CR21","unstructured":"Oxford Centre for Evidence-based Medicine (2009) Levels of evidence. Available at: http:\/\/www.cebm.net\/?o=1025 . Accessed 20 Dec 2012"},{"key":"1746_CR22","doi-asserted-by":"crossref","unstructured":"Dan\u00e9s I, Alerany C, Ferrer A, Vallano A (2013) [Off-label drug use in hospitals.] Med Clin (Barc) Oct 29. pii: S0025-7753(13)00605-2. doi: 10.1016\/j.medcli.2013.09.003","DOI":"10.1016\/j.medcli.2013.09.003"},{"key":"1746_CR23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1741-7015-12-30","volume":"12","author":"M Gatto","year":"2014","unstructured":"Gatto M, Kiss E, Naparstek Y, Doria A (2014) In-\/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med 12:30","journal-title":"BMC Med"},{"key":"1746_CR24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1463-1318.2007.01387.x","volume":"10","author":"MS Sajid","year":"2008","unstructured":"Sajid MS, Vijaynagar B, Desai M, Cheek E, Baig MK (2008) Botulinum toxin vs glyceryltrinitrate for the medical management of chronic anal fissure: a meta-analysis. Colorectal Dis 10:541\u20136","journal-title":"Colorectal Dis"},{"key":"1746_CR25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00384-009-0683-5","volume":"24","author":"WJ Shao","year":"2009","unstructured":"Shao WJ, Li GC, Zhang ZK (2009) Systematic review and meta-analysis of randomized controlled trials comparing botulinum toxin injection with lateral internal sphincterotomy for chronic anal fissure. Int J Colorectal Dis 24:995\u20131000","journal-title":"Int J Colorectal Dis"},{"key":"1746_CR26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Ros\u00e9n K, Hsieh HJ, Saini S, Grattan C, Gimen\u00e9z-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368:924\u201335","journal-title":"N Engl J Med"},{"key":"1746_CR27","unstructured":"European Medicines Agency. Summary of opinion (post authorisation). Xolair EMA\/CHMP\/20684\/2014. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000606\/WC500160092.pdf . Accessed 29 May 2014"},{"key":"1746_CR28","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.clinthera.2012.09.004","volume":"34","author":"R Shimazawa","year":"2012","unstructured":"Shimazawa R, Ikeda M (2012) Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications. Clin Ther 34:2104\u20132116","journal-title":"Clin Ther"},{"key":"1746_CR29","doi-asserted-by":"crossref","unstructured":"Carmona L, Descalzo MA, Ruiz-Montesinos D, Manero-Ruiz FJ, Perez-Pampin E, Gomez-Reino JJ; BIOBADASER 2.0 Study Group (2011) Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford) 50:85\u201392","DOI":"10.1093\/rheumatology\/keq207"},{"key":"1746_CR30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1741-7015-11-238","volume":"11","author":"JR Bellis","year":"2013","unstructured":"Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, Bird KA, Duncan JC, Peak M, Turner MA, Smyth RL, Nunn AJ, Pirmohamed M (2013) Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med 11:238","journal-title":"BMC Med"},{"key":"1746_CR31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00228-010-0800-y","volume":"66","author":"B Ruiz-Antor\u00e1n","year":"2010","unstructured":"Ruiz-Antor\u00e1n B, Agust\u00ed Escasany A, Vallano Ferraz A, Dan\u00e9s Carreras I, Riba N, Mateu Escudero S, Costa J, S\u00e1nchez Santiago MB, Laredo L, Dur\u00e1n Quintana JA, Castillo JR, Abad-Santos F, Payares Herrera C, D\u00edaz S, de Rada B, G\u00f3mez Onta\u00f1\u00f3n E (2010) Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol. Eur J Clin Pharmacol 66:633\u201341","journal-title":"Eur J Clin Pharmacol"},{"key":"1746_CR32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2515\/therapie\/2013039","volume":"68","author":"C Jeunne Le","year":"2013","unstructured":"Le Jeunne C, Billon N, Dandon A, Berda\u00ef D, Adgibi Y, Bergmann JF, Bordet R, Carpentier A, Cohn E, Courcier S, Girault D, Goni S, Jolliet P, Liard F, Prot-Labarthe S, Simon T, Vernotte C, Westerloppe J (2013) Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? Therapie 68:225\u2013239","journal-title":"Therapie"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1746-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1746-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T15:12:11Z","timestamp":1565795531000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1746-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,9]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["1746"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1746-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,9]]}}}